Precision BioSciences Inc (DTIL)

NASDAQ
Currency in USD
Disclaimer
9.6600
+0.5100(+5.57%)
Real-time Data
DTIL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
9.01029.7800
52 wk Range
8.250019.4299
Prev. Close
9.15
Open
9.24
Day's Range
9.0102-9.78
52 wk Range
8.25-19.4299
Volume
47,855
Average Volume (3m)
39,626
1-Year Change
-5.28%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
DTIL Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
33.6000
Upside
+247.8261%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Precision BioSciences Inc Company Profile

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Compare DTIL to Peers and Sector

Metrics to compare
DTIL
Peers
Sector
Relationship
P/E Ratio
4.4x−2.5x−0.6x
PEG Ratio
0.04−0.070.00
Price/Book
0.9x1.4x2.6x
Price / LTM Sales
0.8x31.2x3.2x
Upside (Analyst Target)
227.9%384.1%47.4%
Fair Value Upside
Unlock25.1%6.2%Unlock

People Also Watch

29.63
TDC
-1.13%
18.50
ACI
-0.32%
135.70
CINF
-0.73%
72.48
IPGP
-0.93%
102.69
WYNN
+0.64%

FAQ

What Is the Precision BioSciences (DTIL) Stock Price Today?

The Precision BioSciences (DTIL) stock price today is 9.66. Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

What Stock Exchange Does Precision BioSciences Trade On?

Precision BioSciences is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Precision BioSciences?

The stock symbol for Precision BioSciences is "DTIL."

What Is the Precision BioSciences Market Cap?

As of today, Precision BioSciences market cap is 70.53M.

What is Precision BioSciences Earnings Per Share?

The Precision BioSciences EPS is 3.41.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.